Kasvu Therapeutics raises €30 million in Series A led by Hadean Ventures, with Nordic Science Investments participating
Kasvu Therapeutics raised EUR 30 million in a Series A led by Hadean Ventures, with Nordic Science Investments participating. Funding supports Phase 1/1b development of small-molecule neuroplastogens for depression and other neuropsychiatric or neurodegenerative disorders. Kasvu targets TrkB and BDNF signaling to boost